Data as of Aug 28
| -0.10 / -2.27%|
The 5 analysts offering 12-month price forecasts for Cytokinetics Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +201.62% increase from the last price of 4.31.
The current consensus among 5 polled investment analysts is to Buy stock in Cytokinetics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.